MedTrace Logo

Study to Develop a Breath Analyser to Detect Chronic Kidney Disease

NCT03303222 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-11-04

No results posted yet for this study

Summary

Measure trimethylamine oxide in the breath.

Conditions

Interventions

DIAGNOSTIC_TEST

breath

measurement of volatile compounds, such as TMAO in exhaled breath and blood

Sponsors & Collaborators

  • University College, London

    lead OTHER

Principal Investigators

  • andrew davenport, md · UCL, London

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-10
Primary Completion
2023-11-30
Completion
2023-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03303222 on ClinicalTrials.gov